Drug Profile
Research programme: antibacterials - Deinobiotics
Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Deinove
- Developer CNRS; Deinove; Nosopharm
- Class Antibacterials
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Bacterial infections
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for research development in Bacterial-infections in France
- 26 Mar 2013 Early research is ongoing in France
- 15 Nov 2010 Early research in Bacterial infections in France (unspecified route)